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tion. Thus, ATG3 is an important
factor implicated in steatosis. ATG3 levels are elevated in the livers of mice and patients
with NAFLD.
 Inhibition of ATG3 in human hepatocytes and in mouse liver ame-
liorates steatosis by stimulating SIRT1, CPT1a, and mitochon-
drial function.
 Hepatic knockdown of SIRT1 or CPT1a blunts the ability of ATG3
inhibition to increase mitochondrial activity and to alle-
viate steatosis.https://doi.org/10.1016/j.jhep.2021.09.008
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We show that autophagy-related
gene 3 (ATG3) contributes to the
progression of non-alcoholic fatty
liver disease in humans and mice.
Hepatic knockdown of ATG3 ame-
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enzyme mainly known for its actions in the LC3 lipidation pro-
cess, which is essential for autophagy. Whether ATG3 plays a role
in lipid metabolism or contributes to non-alcoholic fatty liver
disease (NAFLD) remains unknown.
Methods: By performing proteomic analysis on livers from mice
with genetic manipulation of hepatic p63, a regulator of fatty
acid metabolism, we identified ATG3 as a new target down-
stream of p63. ATG3 was evaluated in liver samples from pa-
tients with NAFLD. Further, genetic manipulation of ATG3 waswords: ATG3; sirtuin 1; lipid metabolism; NAFLD; NASH; mitochondria.
eived 18 March 2021; received in revised form 3 August 2021; accepted 13 September
1; available online 21 September 2021
orresponding author. Address: Department of Physiology, Research Centre of
lecular Medicine and Chronic Diseases (CIMUS), Instituto de Investigación
itaria de Santiago de Compostela, Universidadde Santiago de Compostela (USC),
tiago de Compostela, Spain.
ail address: ruben.nogueiras@usc.es (R. Nogueiras).
Contributed equally
s://doi.org/10.1016/j.jhep.2021.09.008
Journal of Hepatologyand in the livers of mice.
Results: ATG3 expression is induced in the liver of animal
models and patients with NAFLD (both steatosis and non-
alcoholic steatohepatitis) compared with those without liver
disease. Moreover, genetic knockdown of ATG3 in mice and hu-
man hepatocytes ameliorates p63- and diet-induced steatosis,
while its overexpression increases the lipid load in hepatocytes.
The inhibition of hepatic ATG3 improves fatty acid metabolism
by reducing c-Jun N-terminal protein kinase 1 (JNK1), which
increases sirtuin 1 (SIRT1), carnitine palmitoyltransferase 1a
(CPT1a), and mitochondrial function. Hepatic knockdown of
SIRT1 and CPT1a blunts the effects of ATG3 on mitochondrial
activity. Unexpectedly, these effects are independent of an
autophagic action.
Conclusions: Collectively, these findings indicate that ATG3 is a
novel protein implicated in the development of steatosis.
Lay summary: We show that autophagy-related gene 3 (ATG3)
contributes to the progression of non-alcoholic fatty liver disease2022 vol. 76 j 11–24
Research Article NAFLD and Alcohol-Related Liver Diseasesin humans and mice. Hepatic knockdown of ATG3 ameliorates
the development of NAFLD by stimulating mitochondrial func-
tion. Thus, ATG3 is an important factor implicated in steatosis.
© 2021 The Author(s). Published by Elsevier B.V. on behalf of Euro-
pean Association for the Study of the Liver. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a major health threat
in both developed and developing countries and is a precursor of
the more advanced liver diseases, including non-alcoholic stea-
tohepatitis (NASH), cirrhosis, and liver cancer. Currently, under-
standing the multiple and complex molecular pathways
implicated in NAFLD onset and progression is a major priority.
The transcription factor p63, which belongs to a family
comprising p53, p63, and p73,1 is one of many factors that con-
tributes to the development of liver steatosis. The role of p63 as a
tumor suppressor and in cell maintenance and renewal is well
studied, but we have recently reported that it is also relevant in the
control of lipid metabolism.2 p63 encodes multiple isoforms that
can be grouped into 2 categories; isoforms with an acidic trans-
activation domain (TA) and those without this domain (domain
negative). The TAp63a isoform is elevated in the liver of animal
models of NAFLD as well as in liver biopsies from obese patients
with NAFLD. Furthermore, downregulation of p63a in the liver at-
tenuates liver steatosis in diet-induced obese (DIO)mice, while the
activation of TAp63a increases hepatic fat content, mediated by the
activation of IKKb and endoplasmic reticulum stress.2
A specialized form of autophagy that degrades lipid droplets,
termed “lipophagy”, is a major pathway of lipid mobilization in
hepatocytes. Lipophagy is elevated inhepatomacells upon exposure
to free fatty acids,3 and reduces the fatty acid load in mouse hepa-
tocytes.4 Its impairment has been associated with the development
of fatty liver and insulin resistance3,5; in contrast, theautophagicflux
is increased during the activation of hepatic stellate cells.6
In the present study, we used an unbiased proteomics approach
to gain insight into novel proteins modulating lipid metabolism in
the liver of mice with genetic knockdown or overexpression of
TAp63a. We found that autophagy-related gene 3 (ATG3) was
upregulated by TAp63a activation and downregulated after p63a
inhibition. ATG3 is elevated in several animalmodels of NAFLD and
in the liver of patientswithNAFLD. Genetic overexpression of ATG3
increased the lipid load in hepatocytes, while its repression alle-
viated TAp63a- and diet-induced steatosis. ATG3 exerted its role in
lipid metabolism by regulating SIRT1 and mitochondrial function.
Collectively, these findings identify ATG3 as a novel factor impli-
cated in the development of steatosis.
Materials and methods
Animals and diets
Mouse experiments were conducted to the standard protocols
approved by the Animal Ethics Committee at the University of
Santiago de Compostela, and mice received the highest levels of
human care. C57BL/6J (8-week-old male) mice were housed in
rooms under constant temperature (22C), a 12:12 h light/dark
cycle and with ad libitum access to standard diet (SD)
(U8200G10R, SAFE), a choline-deficient high-fat diet (CDHFD)
(D05010402; 45 kcal% fat, Research Diets), a methionine- and
choline-deficient diet (A02082002BR, Research Diets), or a high-
fat diet (HFD) (D12492; 60 kcal% fat, Research Diets) used during12 Journal of Hepatologyspecified times and experiments. Food intake and body weight
were measured weekly during all experimental phases.
Cohort of patients with NAFLD
The study population included 55 patients with biopsy-proven
NAFLD (25 with non-alcoholic fatty liver [NAFL], and 30 with
NASH), who underwent a liver biopsy during bariatric surgery
or with a diagnostic purpose at the Santa Cristina University
Hospital (Madrid, Spain) and at the Marqués de Valdecilla Uni-
versity Hospital (Santander, Spain) (Table S1). Liver samples
with histologically normal liver obtained from 32 individuals
during programmed cholecystectomy without steatosis were
selected as healthy controls. Patients consumed <20 g of alcohol/
day, did not take potentially hepatotoxic drugs, had no analyt-
ical evidence of iron overload, and were seronegative for auto-
antibodies and for hepatitis B/C viruses and human
immunodeficiency virus. Hepatic histopathological analysis was
performed according to the scoring system of Kleiner et al.7
Minimal criteria for NASH included the combined presence of
grade 1 steatosis, hepatocellular ballooning, and lobular
inflammation with or without fibrosis. This study was per-
formed in agreement with the Declaration of Helsinki and with
local and national laws. The Human Ethics Committees of the 2
hospitals approved the study procedures, and all participants
voluntarily signed an informed written consent before inclusion
in the study.
Results
Hepatic ATG3 is regulated by p63 and increased in diet-
induced animal models of steatosis
Hepatic overexpression of TAp63a isoform induces steatosis,
while inhibition of p63a ameliorates diet-induced steatosis.2
Proteomic analyses in the liver of these 2 animal models iden-
tified novel pathways and regulators of hepatic lipid accumula-
tion (Fig. 1A-1D). Volcano plots show that multiple changes in
hepatic protein levels were triggered by the manipulation of p63
(Fig. 1A-B). We specifically searched for proteins oppositely
expressed in mice following the overexpression or knockdown of
p63; we found that p63 positively regulated 43 proteins.
Analyzing this protein set revealed a significant over-
representation (44%) of metabolism-related proteins, with
mitochondria identified as the most affected cell component
(Fig. 1C). A heatmap showed several proteins involved in lipid
metabolism with a strong positive regulation by p63 over-
expression, including ATG3 (Fig. 1D). Given the relevant role of
lipophagy in regulating fatty acid metabolism, and that ATG3 has
not previously been related to liver function, we selected this
candidate for further investigation. We corroborated that ATG3
mRNA expression and protein levels were upregulated when
TAp63a was induced in the liver, while it was reduced when
hepatic p63a was inhibited in DIO mice (Fig. 1E).
Next, we evaluated the expression of ATG3 in livers from
mouse models of diet-induced NAFLD and NASH, including mice
fed a HFD or a CDHFD, and found that ATG3 mRNA was elevated
(Fig. 1F). Together, these results indicate that ATG3 expression is
consistently increased in preclinical models of steatosis
and steatohepatitis.
ATG3 is increased in the livers of patients with NAFLD
ATG3 expression was evaluated in liver biopsies from patients
with NAFLD or healthy livers (Table S1). ATG3 mRNA expression2022 vol. 76 j 11–24
was significantly higher in the livers of patients with NAFLD
(both NAFL and NASH) than in those from patients without the
disease (Fig. 2A). ATG3 positively correlated with steatosis grade
(Fig. 2B), NAFLD activity score (Fig. 2C), and fatty liver index
(Fig. 2D). ATG3 levels were increased in obese (BMI>30) vs. non-
obese (BMI<30) patients (Fig. 2E), and positively correlated with
BMI (Fig. 2F). Altogether, these results indicate that higher ATG3
levels are present in patients with NAFLD.ATG3 increases lipid content and reduces b-oxidation in
human hepatocytes
ATG3 mRNA expression (Fig. 3A) and lipid content (Fig. 3B)
were increased in human hepatic THLE2 cells treated with
oleic acid (OA). However, small-interfering (si)RNA-mediated
ATG3 silencing reduced OA-induced lipid storage (Fig. 3B and
Fig. S1A). As previously reported,2 TAp63a overexpression
increased the lipid droplets in hepatocytes, but this effect was
blunted when ATG3 was silenced (Fig. 3C). The transfection
efficiency of the plasmid for p63, and siRNA for ATG3, were
corroborated (Fig. S1B). ATG3 overexpression (Fig. S1C)
increased the lipid content in THLE2 cells (Fig. 3D). Impor-
tantly, similar loss- and gain-of-function experiments in
another human hepatic cell line, HepG2, provided the same
results: the OA-induced lipid content was reduced when ATG3
was silenced (Fig. 3E), while ATG3 overexpression augmented
the lipid load (Fig. S1D and Fig. 3F). The rate of fatty acid b-
oxidation, assessed using 14C-palmitate, was decreased upon
ATG3 overexpression (Fig. 3G). Finally, we isolated hepatocytes
from mice and transfected them with siATG3 and phosphory-
lated ATG3 (Fig. S1E-S1F) and detected an increase and
reduction of fatty acid b-oxidation, respectively, in hepatocytes
previously incubated with OA (Fig. 3H-3I).ATG3 regulates mitochondrial activity in hepatocytes
The overexpression of ATG3 in HepG2 cells decreased oxygen
consumption rate (Fig. 4A). More specifically, basal respiration,
ATP-linked respiration, proton leak, maximal respiration, spare
capacity, and 24 h non-mitochondrial oxygen consumption were
decreased after ATG3 overexpression (Fig. 4A). These results
were consistent with reduced protein levels of the mitochondrial
complexes II (II-SDHB), III, and V (Fig. 4B). No changes were
observed in protein levels of fatty acid synthase (FAS), acetyl CoA
carboxylase, or carnitine palmitoyltransferase 1a (CPT1a)
(Fig. 4C). However, the induction of ATG3 decreased peroxisome
proliferator-activated receptor gamma coactivator 1 alpha
(PGC1a) and sirtuin 1 (SIRT1) (Fig. 4D), 2 proteins that promote
mitochondrial function and fatty acid oxidation.8 These results
were corroborated in isolated hepatocytes, where the over-
expression of ATG3 (Fig. S1E) also reduced protein levels of SIRT1
and PGC1a (Fig. 4E).
ATG3 inhibition in HepG2 cells increased the oxygen con-
sumption rate, with significant stimulation of basal respiration,
ATP-linked respiration, proton leak, maximal respiration, and
non-mitochondrial oxygen consumption (Fig. 4F). This was in
agreement with increased levels of mitochondrial complexes I, II
(II-SDHB), and IV (IV-COX II) (Fig. 4G), and the upregulation of
CPT1a, PGC1a and SIRT1 levels after silencing ATG3 (Fig. 4H, 4I).
The inhibition of ATG3 (Fig. S1F) also increased protein levels of
SIRT1 and PGC1a in primary mouse hepatocytes (Fig. 4J). AllJournal of Hepatologyresults obtained in HepG2 cells were also corroborated in THLE2
cells (Fig. S2).Inhibition of hepatic ATG3 ameliorates CDHFD-
induced steatosis
We next investigated the in vivo relevance of these findings.
Mice were fed a CDHFD for 16 weeks; at week 8, mice were
injected in the tail vein with a lentivirus encoding for a
scrambled short-hairpin (sh)RNA or shRNA against ATG3. No
differences in body weight or feeding were observed (Fig. 5A-
5B). Hepatic ATG3 was decreased after the lentiviral injection
(Fig. 5C). Although the liver mass and circulating triglycerides
and non-esterified fatty acids were not affected by ATG3-
knockdown (Fig. 5D and Table S2), circulating aspartate
aminotransferase (AST) and alanine aminotransferase (ALT)
were significantly lower (Fig. 5E). Consistent with this, hepatic
triglyceride content and Oil Red O staining in liver sections of
mice after ATG3-knockdown showed a lower amount of lipids,
with no differences in fibrotic content (Sirius Red staining)
(Fig. 5F). ATG3 inhibition increased CPT1a, PGC1a, and SIRT1
(Fig. 5G-5H), as well as the mitochondrial complexes I (I-
NDUFB8) and II (II-SDHB) (Fig. 5I) and the activity of mito-
chondrial complex II (Fig. 5J). Functional assays revealed an
increased b-oxidation rate in livers of mice with ATG3-
knockdown (Fig. 5K). These effects were independent of
cellular proliferation since the expression of cyclin D1
and cyclin D2 and the immunostaining of Ki67 were un-
changed between the groups (Fig. S3A-S3B). The knockdown
of ATG3 did not affect mRNA expression of fibrotic
markers (Fig. S4A).Inhibition of hepatic ATG3 ameliorates TAp63a-
induced steatosis
We next evaluated the effects of ATG3 inhibition on TAp63a-
induced steatosis in mice. For this, mice fed a SD were injected
via the tail vein with adeno-associated virus (AAV)8-TAp63a or
AAV8-GFP; and then, after 8 weeks, they were injected again
with either shATG3 (to knockdown ATG3) or scrambled shRNA
(as a control) and maintained on the same diet for another 8
weeks. Body weight (Fig. 6A) and food intake (Fig. 6B) remained
unchanged. Administration of AAV8-TAp63a or lentivirus-
shATG3 caused an increase in p63 and a decrease in ATG3,
respectively (Fig. 6C). Even though liver mass was unchanged
(Fig. 6D), higher circulating AST and ALT levels were observed
after TAp63a overexpression; ATG3 inhibition reduced AST and
ALT levels (ALT was not statistically significant; p = 0.0513)
(Fig. 6E). Serum triglycerides and non-esterified fatty acids were
similar among all groups (Table S3).
As previously reported,2 the overexpression of TAp63a caused
liver steatosis, an effect that was blunted by ATG3-knockdown
(Fig. 6F). Mechanistically, AAV8-TAp63a-treated mice had
elevated levels of the FAS protein and reduced CPT1a, PGC1a, and
SIRT1 (Fig. 6G-H). ATG3 inhibition restored the levels of CPT1a,
PGC1a, and SIRT1 to those of the control group (Fig. 6G-6H).
Hepatic overexpression of TAp63a decreased the levels of all
mitochondrial complexes, while ATG3 inhibition normalized the
liver levels of complexes I and II (Fig. 6I). In these groups, mRNA
expression of fibrotic markers such as collagen alpha 2, collagen
III or aSMA remained unaltered, although collagen alpha 1 was2022 vol. 76 j 11–24 13
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Fig. 1. Hepatic ATG3 is upregulated in different mouse models of NAFLD. (A, B) Volcano plots of hepatic protein expression determined by LC-MS/MS pro-
teomics of (A) mice fed a SD, with TAp63a overexpressed specifically in liver compared to the control group (n = 3 per group). Upregulated proteins (blue) and
downregulated proteins (brown); or (B) mice fed a CDHFD for 12 weeks, with hepatic p63a downregulated as compared to the control group (n = 3 per group).
Upregulated proteins (orange) and downregulated (violet). Values obtained for ATG3 are represented in the bar graph. (C) Reactome pathway classification of
14 Journal of Hepatology 2022 vol. 76 j 11–24














































































Fig. 2. ATG3 is increased in the liver of patients with NAFLD. (A) ATG3mRNA expression in the liver of patients without NAFLD (NL) (n = 32), with NAFL (n = 25)
or NASH (n = 30). (B) Correlation between ATG3 and steatosis grade. (C) Correlation between ATG3 and NAS score. (D) Correlation between ATG3 and fatty liver
index. (E) ATG3 mRNA expression in the liver of non-obese vs. obese patients with NAFLD. (F) Correlation between ATG3 and body mass index. HPRT was used to
normalize mRNA levels. Data are presented as mean ± standard deviation. p value using a Student’s t test (B) (C) (D) (E) (F) or one-way ANOVA followed by a
Newman-Keuls multiple comparison test (A). FLI, fatty liver index; NAFL, non-alcoholic fatty liver; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity
score; NASH, non-alcoholic steatohepatitis; NL, normal liver.
=
elevated by TAp63a and reduced when ATG3 was inhibi-
ted (Fig. S4B).Knockdown of hepatic ATG3 does not affect fibrosis
We next evaluated whether ATG3-knockdown in liver alleviates
fibrosis by injecting mice via the tail vein with a lentivirus
shATG3 or shRNA-scrambled (as control); mice were fed a SD for
4 week and a methionine- and choline-deficient diet for another
4 weeks to induce fibrosis, and were sacrificed at week 8.9 Body
weight was similar between ATG3-knockdown and control mice
(Fig. S5A). As expected, ATG3-knockdown significantly reduced
ATG3 mRNA (Fig. S5B). No differences were observed for liver
mass (Fig. S5C), serum AST or ALT (Fig. S5D), inflammatory or
profibrotic markers (Fig. S5E), or Oil Red O or Sirius Red staining
(Fig. S5F). Of note, ATG3 was highly expressed in isolated hepatic
stellate cells compared to hepatocytes or Kupffer cells (Fig. S6A)
and in LX2 cells (a human hepatic stellate cell line) compared to
THLE2 and HepG2 cells (Fig. S6B). However, the treatment of LX2
cells with TGFb did not change ATG3 expression, and the TGFb-
induced expression of fibrotic markers was not affected after
silencing ATG3 (Fig. S6C-S6D).deregulated proteins in liver of mice from (A) and (B), showing the number of pro
also classified according to the cellular component using FunRich tool. (D) Heatm
(A) and (B). (E) mRNA levels of p63 and ATG3, as well as ATG3 protein levels, in mic
mice fed a SD, an HFD, or a CDHFD (n = 9–14 per group). HPRT and GAPDH were us
the same gel. Data are presented as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001,
high-fat diet; FDR, false discovery rate; HFD, high-fat diet; LC-MS/MS, liquid c
disease; SD, standard diet; sh(RNA), short-hairpin (RNA); WT, wild-type.
Journal of HepatologyATG3 requires SIRT1 to modulate lipid metabolism and
mitochondrial activity
We next assessed the functional relevance of SIRT1 as a potential
modulator of ATG3. Similar to the results shown in Fig. 3B,
silencing ATG3 in HepG2 cells ameliorated OA-induced lipid load
(Fig. S7A). However, when SIRT1 was also silenced, siATG3 failed
to decrease OA-induced lipid content (Fig. S7A). These results
were also corroborated in THLE2 cells co-transfected with siATG3
and siSIRT1 (Fig. S7B). Moreover, the higher oxygen consumption
rate induced by siATG3 in THLE2 cells was also lost after SIRT1
silencing (Fig. S7C). In addition, ATG3-induced lipid content was
blunted by resveratrol, a pharmacological activator of SIRT1 in
both THLE2 cells (Fig. S8A) and primary hepatocytes (Fig. S8B). In
isolated hepatocytes, ATG3 also reduced the oxygen consump-
tion rate while resveratrol blunted this effect (Fig. S8C). In line
with these results, silencing ATG3 increased SIRT1 activity and
reduced acetylated levels of PGC1a, while its overexpression
reduced SIRT1 activity in isolated hepatocytes (Fig. S9A-S9C).
Next, we evaluated the in vivo relevance of SIRT1 as a medi-
ator of the effects of ATG3. For this, mice fed a CDHFD were
injected with a lentivirus encoding either a scrambled shRNA (asteins included in each category and the associated FDR. The same proteins were
ap representation of protein levels differentially expressed in the groups from
e in the conditions as in (A) and (B). (n = 4 per group). (F) ATG3mRNA in liver of
ed to normalize mRNA and protein levels, respectively. Lines indicate splicing in
using a Student’s t test. AAV, adeno-associated virus; CDHFD, choline-deficient
hromatography tandem mass spectrometry; NAFLD, non-alcoholic fatty liver












































































































































































































































































































































































































































































































































Fig. 3. ATG3 regulates lipid accumulation in human hepatic cell lines. (A) ATG3 mRNA in THLE2 cells treated with OA (1 mM) for 24 h (n = 6 per group). (B–F)
Representative Oil Red O staining of (B) THLE2 cells with siATG3 treated with OA or vehicle (n = 6 per group); (C) TAp63a-upregulated THLE2 cells after ATG3
silencing (n = 15 per group); and (D) THLE2 cells with overexpression of ATG3 (n = 12 per group). (E, F) Representative Oil Red O staining of HepG2 cells with ATG3
downregulated (E) or ATG3 overexpressed (F), treated with OA or vehicle for 24 h (n = 4–7 per group). (G) Palmitate oxidation rate (partial and complete
oxidation) in HepG2 cells overexpressing ATG3. Palmitate oxidation rate in mouse hepatocytes after overexpression (H) and inhibition (I) of ATG3. The n rep-
resents the number of independent experiments. Data are presented as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001, using a Student’s t test (A) (D) (F) (G) or one-
way ANOVA followed by a Newman-Keuls multiple comparison test (B) (C) (E). ASM, acid soluble metabolites; OA, oleic acid; si(RNA), small-interfering RNA; TA,
transactivation domain.
16 Journal of Hepatology 2022 vol. 76 j 11–24
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Fig. 4. ATG3 modulates mitochondrial function in hepatocytes. HepG2 cells overexpressing ATG3 were analyzed for (A) OCR, (B) protein levels of OXPHOS
complex subunits I–V, (C) lipid metabolism markers, and (D) protein levels of PGC1a and SIRT1 (n = 6 per group). (E) PGC1a and SIRT1 protein levels of primary
mouse hepatocytes overexpressing ATG3 (n = 5 per group). ATG3-silenced HepG2 cells were analyzed for (F) OCR, (G) protein levels of OXPHOS complex subunits
I–V, (H) lipid metabolism markers, and (I) protein levels of PGC1a and SIRT1 (n = 5–6 per group). (J) PGC1a and SIRT1 protein levels of ATG3-silenced primary
mouse hepatocytes (n = 6 per group). The n represents the number of independent experiments. GAPDH was used to normalize protein levels. Dividing lines
indicate splicing in the same gel. Data are presented as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001, using a Student’s t test. OCR, oxygen consumption rate;
OXPHOS, oxidative phosphorylation.a control) or shRNA-ATG3. At week 4, a second lentiviral vector
with shRNA-scrambled or shRNA-SIRT1 was injected; and mice
were sacrificed at week 8. Body weight and food intake remained
unchanged (Fig. 7A-7B). ATG3 and SIRT1 were reduced in liverJournal of Hepatologyafter the injections of shRNA-ATG3 and shRNA-SIRT1, respec-
tively (Fig. 7C). Even though liver weight was not affected, AST
and ALT were reduced after ATG3-knockdown, and this reduc-






































































































































































































































































































































































































































































Fig. 5. Liver-specific downregulation of ATG3 ameliorates NAFLD induced by CDHFD. (A) Body weight change, (B) food intake, (C) hepatic ATG3 protein levels,
and (D) liver mass of mice fed CDHFD for 16 weeks, with lentivirus of shRNA ATG3 or shRNA–scrambled delivered via TVI at week 8, as indicated. (E) Serum levels
of AST and ALT. (F) Representative microphotographs of H&E (upper panel), Oil Red O (middle panel) and Sirius Red staining (lower panel) of liver sections. Lipids
in Oil Red O-stained sections and collagen deposition in Sirius Red stained sections (pink area) were quantified using ImageJ. Hepatic triglyceride content was also
directly measured. (G) Hepatic protein levels of lipid metabolismmarkers. (H) Liver proteins levels of PGC1a and SIRT1. (I) Liver protein levels of OXPHOS complex
subunits I–V. (J) Complex II activity in liver. (K) Hepatic palmitate oxidation rate (partial and complete oxidation). GAPDH and HPRT were used to normalize
protein and mRNA levels, respectively. Dividing lines indicate splicing in the same gel. Data are presented as mean ± SEM; *p <0.05, **p <0.01, ***p <0.001, using a
Student’s t test (n = 7–15 per group). ASM, acid soluble metabolites; CDHFD, choline-deficient high-fat diet; OXPHOS, oxidative phosphorylation; sh(RNA), short-
hairpin (RNA); TVI, tail vein injection.
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Fig. 6. Liver-specific downregulation of ATG3 ameliorated NAFLD induced by TAp63a. (A) Body weight change, (B) food intake, (C) hepatic levels of TAp63a
mRNA and ATG3 protein, and (D) liver mass of mice fed a SD for 16 weeks, with TVI of AAV8–TAp63a or AAV8–GFP at week 1, and a second TVI of lentivirus
encoding the shRNA-ATG3 or shRNA-scrambled control at week 8, as indicated. (E) Serum levels of AST and ALT. (F) Representative microphotographs of H&E
(upper panel) and Oil Red O staining (lower panel) of liver sections. Oil Red O-stained sections were quantified using ImageJ. Hepatic triglyceride content was also
directly measured. (G) Hepatic protein levels of lipid metabolism markers. (H) Liver protein levels of PGC1a and SIRT1. (I) Liver protein levels of OXPHOS complex
subunits I–V. Protein levels were normalized to GAPDH and HPS70, and mRNA levels, to HPRT. Dividing lines indicate splicing in the same gel. Data are presented
as mean ± SEM; *p <0.05, **p <0.01, using one-way ANOVA followed by a Newman-Keuls Multiple comparison test (n = 7–10 per group). AAV, adeno-associated
virus; NAFLD, non-alcoholic fatty liver disease; OXPHOS, oxidative phosphorylation; SD, standard diet; sh(RNA), short-hairpin (RNA); TA, transactivation domain;
TVI, tail vein injection.
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Fig. 7. Inhibition of SIRT1 blunts the effects of liver-specific downregulation of ATG3 in NAFLD. (A) Body weight change, (B) food intake, (C) hepatic levels of
ATG3 protein and SIRT1 mRNA, and (D) liver mass in mice fed CDHFD for 8 weeks, with a lentivirus with shRNA-ATG3 or shRNA-scrambled at week 1, and a
second TVI of lentivirus with shRNA-SIRT1 or shRNA-scrambled at week 4, as indicated. (E) Serum levels of AST and ALT. (F) Representative microphotographs of
Oil Red O (upper panel) and H&E staining (lower panel) of liver sections. Oil Red O staining was quantified using ImageJ. Hepatic triglyceride content was also
directly measured. (G) Hepatic protein levels of lipid metabolism markers. (H) Liver protein levels of OXPHOS complex subunits I–V. (I) Hepatic Complex II
activity. Protein levels were normalized with GAPDH, and mRNA levels, with HPRT. Dividing lines indicate splicing in the same gel. *p <0.05, **p <0.01, ***p <0.001,
using one-way ANOVA followed by a Newman-Keuls Multiple Comparison Test (n = 9–10 per group). CDHFD, choline-deficient high-fat diet; NAFLD, non-
alcoholic fatty liver disease; OXPHOS, oxidative phosphorylation; sh(RNA), short-hairpin (RNA); TVI, tail vein injection.
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(Fig. 7D-7E). The reduced lipid content and hepatic triglycerides
in mice with ATG3-knockdown was blunted when SIRT1 was
subsequently inhibited (Fig. 7F). The knockdown of hepatic ATG3
caused an increase in CPT1a protein levels as well as a higher
activity of complex II, but these effects were blocked by co-
silencing ATG3 and SIRT1 (Fig. 7G-7I). On the other hand, the
expression of fibrotic markers remained unchanged between the
groups (Fig. S4C).
ATG3 regulates protein levels of SIRT1 via JNK1
A key factor in regulating SIRT1 protein levels is c-Jun N-terminal
kinase 1 (JNK1), whose activation induces SIRT1 protein degra-
dation,10 while JNK2 induces SIRT1 protein stability.11 We
measured JNK1 and JNK2 in the liver of mice fed a CDHFD where
ATG3 was knocked down in the liver and detected reduced levels
of JNK1 but not JNK2 (Fig. S10A). Consistent with in vivo data,
silencing ATG3 in THLE2 cells reduced JNK1 (Fig. S10B), while the
induction of ATG3 increased JNK1 (Fig. S10C). Silencing ATG3 in
primary hepatocytes decreased JNK1 (Fig. S10D), while its over-
expression increased JNK1 (Fig. S10E). Finally, treatment of iso-
lated hepatocytes with the JNK1 inhibitor SP600125 blunted the
ATG3-induced actions, including increased lipid content,
reduced oxygen consumption rate and SIRT1 activity (Fig. S10F-
10H). Although a previous report found that modulation of
ATG3 in the adipose tissue activates the Nrf2/Keap1 signaling
pathway in the liver,12 the expression of Nrf2 and Keap1 in the
white adipose tissue and liver of mice fed a CDHFD where ATG3
was knocked down remained unaltered (Fig. S11A-11C). Similar
results were found in the white adipose tissue of mice where
Tap63a was manipulated (Fig. S11D) and in isolated hepatocytes
after silencing ATG3 (Fig. S11E).
ATG3 requires CPT1a to modulate lipid metabolism and
mitochondrial activity
CPT1a floxed mice fed a CDHFD were injected with AAV8-GFP
(control) or AAV8-Cre; at week 4, experimental groups were
injected with either scrambled shRNA (control) or shRNA-ATG3,
and mice were sacrificed at week 8. Body weight remained un-
changed (Fig. S12A). CPT1a and ATG3 levels in livers were
reduced after AAV8-Cre or shRNA-ATG3 treatment, respectively
(Fig. S12B). Liver mass was not affected, but AST and ALT levels
were lower after ATG3-knockdown; these levels returned to
baseline when both ATG3 and CPT1a were silenced (Fig. S12C-
12D). The reduced lipid and hepatic triglyceride content and
increased levels of complex II and IV in mice with ATG3 down-
regulation were blunted when CPT1a was also reduced
(Fig. S12E-12F). The expression of fibrotic markers was not
altered between these groups (Fig. S12G).
ATG3 regulates hepatic lipid content in an autophagy-
independent manner
To further explore whether ATG3 exerts its hepatic actions via an
autophagy-dependent process, we used both THLE2 and HepG2
hepatocyte cell lines to manipulate ATG3. Upon induction of
autophagy, microtubule-associated protein 1 light chain 3 alpha
(MAP1LC3A or LC3) is lipidated, and this LC3-phospholipid
conjugate (LC3-II) is recruited to autophagosomal membranes
and fuses with lysosomes to form autolysosomes, which degrade
intra-autophagosomal components and LC3-II.13,14 As expected,
silencing ATG3 in HepG2 cells decreased LC3-II levels (Fig. 8A).
We then monitored the autophagic flux by analyzing LC3-IIJournal of Hepatologyturnover, in the presence or absence of the inhibitor of
lysosome-mediated proteolysis, chloroquine (CQ). CQ adminis-
tration induced the expected LC3-II accumulation (Fig. 8A). He-
patocytes treated with OA and transfected with siATG3 stored
fewer lipids, and CQ treatment increased the lipid content
(Fig. 8B). Strikingly, however, in cells overexpressing ATG3, in-
hibition of autophagy by CQ did not affect ATG3-induced lipid
droplets in THLE2 or HepG2 cells (Fig. 8C-8D). Thus, these results
suggested that the lipid accumulation induced by ATG3 is inde-
pendent of autophagy. This was confirmed in vivo, as ATG3-
knockdown in our 2 animal models of steatosis (induced by
TAp63a or CDHFD) reduced LC3-II accumulation but did not
affect protein and mRNA levels of well-established markers of
autophagy such as ATG5, ATG7, and p62 (Fig. 8E-8F). Overall,
these data indicate that the effects of ATG3 on lipid content are
independent of its autophagic action. This is also supported by
the fact that autophagy contributes to the turnover of lipid
droplets, and thereby to an increased fatty acid oxidation, a
process named lipophagy.15,16
Discussion
In this work, we identified for first the time the role of ATG3 on
fatty acid metabolism and its implications in the development of
NAFLD. ATG3 is elevated in the liver of animal models as well as
patients with NAFLD. Moreover, in vitro and in vivo genetic
functional studies indicated that the overexpression of ATG3
favors lipid deposition, while its silencing alleviates steatosis
induced by OA, p63, or diet. These novel findings expand our
knowledge about the molecular mechanisms involved in
liver steatosis.
Autophagy has a well-established role in hepatic lipid meta-
bolism, insulin sensitivity, and cellular injury, suggesting
different potential mechanistic roles for autophagy in NAFLD.17,18
Our initial hypothesis was that ATG3, an enzyme that catalyzes
the LC3 lipidation process essential for autophagocytosis,19 ex-
erts its effects through an autophagic action, as p63 (as well as its
family co-members p53 and p73) can induce autophagy.20,21
Contrary to our expectations, we found that ATG3 modulates
lipid metabolism via non-autophagic mechanisms but in a JNK1-
and SIRT1-dependent manner. ATG3 increases JNK1 protein
levels, which are known to induce SIRT1 protein degradation.10
The lower protein levels of SIRT1, concomitant to its inhibited
activity in human hepatocytes and murine liver reduced fatty
acid oxidation and mitochondrial function, leading to a higher
lipid load. In agreement with this, the inhibition of ATG3
decreased JNK1 and increased protein levels of SIRT1 and mito-
chondrial function, ultimately decreasing lipid content. Indeed,
many reports have demonstrated a key role of SIRT1 in stimu-
lating mitochondrial function22 and fatty acid oxidation,23,24
which contribute to attenuating hepatic steatosis.25 Our find-
ings show that the protection against steatosis induced by the
inhibition of ATG3 was lost when SIRT1 and CPT1a were also
suppressed in cells and mice, indicating a functional role for
SIRT1 and CPT1a in the anti-steatotic action, which was not
associated with changes in autophagic flux. Our results in the
liver are opposite to the actions of ATG3 in adipose tissue, where
depletion of ATG3 triggered the Nrf2/Keap1 pathway in the
liver.12 However, it is important to note that mice lacking ATG3 in
adipose tissue displayed increased adipose tissue inflammation,
systemic insulin resistance and accumulation of lipid peroxides,
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Fig. 8. ATG3 regulates hepatic lipid accumulation in an autophagy-independent manner. HepG2 cells silencing ATG3 were treated for 24 hours with 1 mM OA
and 60 lM CQ (added 18 h after OA) (n = 3-4 per group). (A) LC3-I and LC3-II protein levels. (B) Representative microphotographs of Oil Red O staining. Oil Red O
staining was quantified using ImageJ and normalized to the total number of nuclei per field. (C) HepG2 cells and (D) THLE2 cells overexpressing ATG3 were
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On the other hand, it has also been reported that there is a
tissue-specific autophagy response.26–28
It is important to highlight that most, if not all, components of
the molecular machinery for autophagy mediate effects that do
not depend on lysosomal degradation of autophagy sub-
strates.29,30 Consequently, numerous, distinct non-autophagic
biological functions for different ATG proteins have been re-
ported, including cell survival, modulation of cellular transport,
secretory processes, signaling, transcriptional/translational re-
sponses, and membrane reorganization.29,30 More specifically,
ATG3 has been shown to modulate in an autophagic-
independent manner diverse cellular processes such as phago-
cytosis, secretion and exocytosis and cell proliferation.30 Our
study indicating that the effects of ATG3 are modulated by JNK1,
SIRT1 and CPT1a points to another, previously undescribed non-
autophagic action. Importantly, our results also propose that
different ATGs have opposite actions in the liver, at least in terms
of fatty liver disease. While we demonstrated that inhibition of
ATG3 ameliorates NAFLD, liver-specific deletion of ATG5, ATG7,
or ATG14 exacerbate the susceptibility of mice to develop NAFLD
in response to a HFD.31–34 However, the loss of autophagic fac-
tors does not always involve negative actions. For example, mice
lacking ATG5 specifically in the liver are protected against
acetaminophen-induced liver injury.35 These paradoxical actions
of autophagy might occur after long periods in response to
cellular compensatory mechanisms.
The ameliorated steatosis after ATG3-knockdown, and sub-
sequent increased SIRT1 and CPT1a protein levels, was associ-
ated with stimulated mitochondrial function. The link between
ATG3 and mitochondrial homeostasis has been studied before in
the context of cell death, pluripotency acquirement, and main-
tenance of embryonic stem cells.36,37 Although those studies
suggested that the effects of ATG3 on mitochondria are depen-
dent on autophagy, disruption of ATG3/ATG12 conjugation does
not affect starvation-induced autophagy,37 supporting an
autophagic-independent role of ATG3.
In addition to the unexpected mechanism used by ATG3,
another important feature is that ATG3 levels are elevated in the
livers of different animal models and patients with steatosis and
NASH, while its genetic inhibition in mice only alleviated stea-
tosis but did not alter fibrosis. Although ATG3 does not seem to
be differentially expressed in the late stages of NAFLD compared
to initial phases, it is important to consider that a fraction of
people with NAFL will develop NASH or advanced liver
fibrosis,38–40 implying that specific signaling mechanisms are
involved in liver disease progression. Considering that ATG3
overexpression is an early dysregulated mechanism and that
levels of ATG3 remain high during advanced NASH, it could be of
interest for diagnosis and/or as a therapeutic target to prevent
the progression of the disease.
In summary, our findings show for the first time that: a) ATG3
expression increased in the liver of mouse models and of pa-
tients with NAFLD, who also show a positive correlation betweentreated for 24 hours with 1 mM OA and 60 lM CQ (added 18 h after OA) (n = 4
represents the number of independent experiments. (E) Protein levels of autophag
a TVI of AAV8-TAp63a or AAV8-GFP at week 1, and a second TVI of lentivirus with
mice fed a CDHFD with hepatic ATG3 downregulation (n = 7-15 per group) (F). Pro
lines indicate splicing in the same gel. Data are presented as mean ± SEM; *p <
followed by a Newman-Keuls Multiple Comparison Test (E). AAV, adeno-associate
SD, standard diet; sh(RNA), short-hairpin (RNA); TVI, tail vein injection.
Journal of HepatologyATG3 with steatosis grade and NAFLD activity score; b) ATG3
overexpression induced lipid load, and its inhibition in the liver
ameliorated TAp63a- and diet-induced liver steatosis; c) this
anti-steatotic action is mediated by reduction of JNK1 and
increased levels of SIRT1, CPT1a, fatty acid oxidation, and mito-
chondrial function, in an autophagic-independent manner
(Fig. S13). Overall, our results point towards ATG3 as a novel
molecule implicated in the development of steatosis.
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